EcoDrugPlus

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSPNAG00000006090
Gene Symbol: LOC108413498
2 Cross references
211 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-1-Like

Ensembl ID : ENSPNAG00000012580
Gene Symbol: LOC108413880
3 Cross references
211 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4

Ensembl ID : ENSPNAG00000026955
Gene Symbol: LOC108434427
3 Cross references
204 Possible Orthologues:

Voltage-Dependent N-Type Calcium Channel Subunit Alpha-1b-Like

Ensembl ID : ENSPNAG00000021842
Gene Symbol: LOC108423713
3 Cross references
219 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-2 Subunit

Ensembl ID : ENSPNAG00000029725
Gene Symbol: LOC108434911
3 Cross references
247 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSPNAG00000003191
Gene Symbol: LOC108439097
2 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSPNAG00000016632
Gene Symbol: LOC108412836
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSPNAG00000004838
Gene Symbol: LOC108439892
3 Cross references
167 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSPNAG00000027618
Gene Symbol: LOC108439910
3 Cross references
182 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSPNAG00000006066
Gene Symbol: LOC108439893
3 Cross references
186 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-1-Like

Ensembl ID : ENSPNAG00000001242
Gene Symbol: LOC108432549
3 Cross references
226 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-2-Like

Ensembl ID : ENSPNAG00000012572
Gene Symbol: LOC108433686
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).